Vistagen Therapeutics Inc Corporate Update Transcript
Good day, everyone. Thank you for standing by. Welcome to the Vistagen Therapeutics Corporate Update Conference Call and Webcast. Please note that today's conference is being recorded.
At this time, I'd like to turn the conference over to your host, Mark Mcpartland, Senior Vice President, Investor Relations at Vistagen. Mark, please go ahead.
Thank you, Michelle, and good morning, everyone. Welcome, and thank you for joining us. In a press release issued earlier this morning, Vistagen announced top-line results and post-hoc analyses of data from our Palisade 4 Phase 3 Public Speaking Challenge Trial, evaluating [tazodionol] for acute treatment of social anxiety disorder as well as our planned next steps in the pazodienol program. The announcement is available in the investor section of our website.
During today's call, we will briefly review the Palisade 4 top-line and post-hoc data, provide perspective on the findings within the broader Fasedienol
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
